Pirfenidone prevents the progression of irreversible glomerular sclerotic lesions in rats

Nephrology

Volumn 3, Issue 5, 1997, Pages 315-322

  Shimizu, Fujio ^a   Fukagawa, Masafumi ^b   Yamauchi, Shitotomo ^c   Taniyama, Masayoshi ^d   Komemushi, Sadao ^e   Margolin, Solomon B ^f   Kurokawa, Kiyoshi ^b  

^a NIIGATA UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c KDL Inc   (Japan)

^d Narita Memorial Hospital   (Japan)

^e KINKI UNIVERSITY   (Japan)

^f Mornac Incorporated   (United States)

Author keywords

Anti Thy 1 monoclonal antibody; Extracellular matrix; Glomerular sclerosis; Pirfenidone; Proteinuria; Transforming growth factor

Indexed keywords

PIRFENIDONE; PYRIDONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; FEMALE; GLOMERULOSCLEROSIS; IMMUNOHISTOCHEMISTRY; INTERSTITIAL NEPHRITIS; MICROSCOPY; NEPHRECTOMY; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEINURIA; RAT;

EID: 0030822476     PISSN: 13205358     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1797.1997.tb00249.x     Document Type: Article

References (16)

1. Margolin SB, Lefkowitz S. Pirfenidone: A novel pharmacologie agent for prevention and resolution (removal) of lung fibrosis. FASEB J. 1994; 8: A382.
2. Margolin SB. Investigational new drug brochure 'Pirfenidone'. Dallas, Texas Marmac Inc. January 1996.
3. Iyer SN, Wild JS, Schiedt MJ, Hyde DM, Margolin SB, Giri SN. Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters. J. Lab. Clin. Med. 1995; 125: 779-85.
4. Suga H, Teraoka S, Ota K et al. Preventive effect of pirfenidone against experimental sclerosing peritonitis in rats. Exp. Toxic. Pathol. 1995; 47: 287-91.
5. Cheng QL, Orikasa M, Morioka T et al. Progressive renal lesions induced by administration of monoclonal antibody 1-22-3 to unilaterally nephrectomized rats. Clin. Exp. Immunol. 1995; 102: 181-5.
6. Kawachi H, Orikasa M, Matsui K et al. Epitope-specific induction of mesangial lesions with proteinuria by a MoAb against mesangial cell surface antigen. Clin. Exp. Immunol. 1992; 88: 399-404.
7. Weichselbaum TE. An accurate and rapid method for the determination of proteins in small amounts of blood serum and plasma. Am. J. Clin. Pathol. 1946; 10: 40-6.
8. Raij L, Azar S, Keane W. Mesangial immune injury, hypertension and progressive gomerular damage in Dahl rats. Kidney Int. 1984; 26: 137-43.
9. Flanders KC, Roberts AB, Ling N, Fleurdleye BE, Sporn MB. Antibodies to peptide determinants in transforming growth factor-β and their applications. Biochem. 1988; 27: 739-46.
10. Border WA, Ruoslahti E. Transforming growth factor beta: The dark side of tissue repair. J. Clin. Invest. 1992; 90: 1-7.
11. Johnson RJ. Role of cytokines and growth factors in glomerulonephritis: A chance for future therapeutic intervention. Nephron 1996; 73: 506-14.
12. Border WA, Okuda S, Languino LR, Sporn MB, Ruoslahti E. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor β1. Nature 1990; 346: 371-4.
13. Johnson RJ, Raines EW, Floege J et al. Inhibition of mesangial cell proliferation and matrix expansion in glomerulonephritis in the rat by antibody to platelet-derived growth factor. J. Exp. Med. 1992; 175: 1413-16.
14. Border WA, Moble NA, Yamamoto T et al. Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease. Nature 1992; 360: 361-3.
15. Stahl RAK, Thaiss F, Wentzel U, Heimchen U. Morphologic and functional consequences of immune-mediated mesangiolysis; development of chronic glomerular sclerosis. J. Am. Soc. Nephrol. 1992; 2: S144-8.
16. Klahr S. Role of dietary protein and blood pressure in the progression of renal disease. Kidney Int. 1996; 49: 1783-6.